Why DermTech Stock Gained 26% Last Month

Shares of DermTech (NASDAQ: DMTK), a biotech company focused on skin-cancer testing, gained last month as the company continued to attract positive analyst attention and build on momentum from last December. Back then, the company announced results from a TRUST study that showed that its Pigmented Lesion Assay (PLA), its non-invasive skin-cancer test, was 99% accurate when it showed negative results.

According to data from S&P Global Market Intelligence, the stock finished January up 26%. The chart below shows the stock's trajectory for the month.

Continue reading

Source Fool.com